Choroidal Neovascularization Market Report 2026

Choroidal Neovascularization Market Overview

• Choroidal Neovascularization market size has reached to $4.18 billion in 2025 • Expected to grow to $5.99 billion in 2030 at a compound annual growth rate (CAGR) of 7.4% • Growth Driver: Increasing Prevalence Of Age-related Macular Degeneration Driving Market Growth • Market Trend: Advancements In Treatment For Eye Disease With Photodynamic Therapy • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Choroidal Neovascularization Market?

Choroidal neovascularization (CNV) is the abnormal growth of blood vessels in the choroid layer of the eye, often extending into the retina. These newly formed blood vessels are fragile and prone to leaking fluid or blood, which can damage the retinal tissues, leading to vision distortion or loss. The main treatment types of choroidal neovascularization are anti-angiogenic therapy, laser photocoagulation, photodynamic therapy, verteporfin sodium, ranibizumab, bevacizumab, aflibercept, and pegaptanib sodium. Anti-angiogenic therapy is a treatment that inhibits the formation of new blood vessels (angiogenesis), which can help prevent the growth of abnormal blood vessels. These treatments are commonly used based on the specific indications such as age-related macular degeneration (AMD), diabetic macular edema (DME), central serous chorioretinopathy (CSC), polypoidal choroidal vasculopathy (PCV), myopic macular degeneration (MMD), and other related conditions. The route of administration can vary, with options including intravitreal, subconjunctival, periocular, or oral administration. These therapies are primarily administered in hospitals, ophthalmology clinics, and ambulatory surgical centers.

What Is The Choroidal Neovascularization Market Growth Forecast?

The choroidal neovascularization market size is expected to see strong growth in the next few years. It will grow to $5.99 billion in 2030 at a compound annual growth rate (CAGR) of 7.4%. The growth in the forecast period can be attributed to increasing aging population, rising focus on early ophthalmic intervention, expansion of combination therapy approaches, growing investments in retinal disease research, increasing adoption of personalized treatment protocols. Major trends in the forecast period include increasing adoption of anti-vegf therapies, rising use of treat-and-extend regimens, growing demand for early cnv diagnosis, expansion of advanced retinal imaging techniques, enhanced focus on vision preservation therapies.

Global Choroidal Neovascularization Market Segmentation

1) By Treatment Type: Anti-Angiogenic Therapy, Laser Photocoagulation, Photodynamic Therapy, Verteporfin Sodium, Ranibizumab, Bevacizumab, Aflibercept, Pegaptanib Sodium 2) By Indication: Age-Related Macular Degeneration (AMD), Diabetic Macular Edema (DME), Central Serous Chorioretinopathy (CSC), Polypoidal Choroidal Vasculopathy (PCV), Myopic Macular Degeneration (MMD), Other Indications 3) By Route Of Administration: Intravitreal, Subconjunctival, Periocular, Oral 4) By End User: Hospitals, Ophthalmology Clinics, Ambulatory Surgical Centers, Research Centers Subsegments: 1) By Anti-Angiogenic Therapy (Anti-VEGF Therapy): Ranibizumab, Bevacizumab, Aflibercept, Pegaptanib Sodium 2) By Laser Photocoagulation: Thermal Laser Photocoagulation, MicroPulse Laser Therapy 3) By Photodynamic Therapy (PDT): Standard PDT, Low-Fluence PDT, Half-Dose PDT 4) By Verteporfin Sodium: Intravenous Administration, Combination Therapy With Anti-VEGF 5) By Ranibizumab: Monthly Dosing, As-Needed Dosing, Treat-and-Extend Regimen 6) By Bevacizumab: Off-Label Use, Compounded Intravitreal Injections 7) By Aflibercept: Fixed-Dosing Regimen, Treat-and-Extend Regimen 8) By Pegaptanib Sodium: Monotherapy, Combination Therapy

What Is The Driver Of The Choroidal Neovascularization Market?

The rising prevalence of age-related macular degeneration (AMD) is expected to propel the growth of the choroidal neovascularization (CNV) market going forward. Age-related macular degeneration (AMD) is an eye disease that gradually damages the macula, leading to central vision loss, primarily in older adults. The rising prevalence of age-related macular degeneration (AMD) is due to the aging population, increased life expectancy, lifestyle changes, genetic factors, and greater exposure to environmental risks. Choroidal neovascularization (CNV) supports age-related macular degeneration (AMD) patients by contributing to the development of wet AMD, where the growth of abnormal blood vessels beneath the retina leads to vision deterioration, requiring advanced treatments such as anti-VEGF therapy to manage choroidal neovascularization (CNV) and slow the progression of age-related macular degeneration (AMD), ultimately preserving central vision in affected individuals. For instance, in 2025, according to the UHN Foundation, Canada-Based official fundraising arm, age-related macular degeneration (AMD) is the primary cause of significant, irreversible vision loss in individuals over 50. Currently affecting over 200 million people globally, this number is projected to rise to 288 million by 2040. Therefore, the increasing prevalence of age-related macular degeneration is driving the growth of the choroidal neovascularization industry.

Key Players In The Global Choroidal Neovascularization Market

Major companies operating in the choroidal neovascularization market are Roche Holding AG, Regeneron Pharmaceuticals Incorporated, Bayer Aktiengesellschaft, Novartis AG, Apellis Pharmaceuticals Incorporated, Kodiak Sciences Incorporated, Adverum Biotechnologies Incorporated, Clearside Biomedical Incorporated, Graybug Vision Incorporated, Outlook Therapeutics Incorporated, Oxurion NV, 4D Molecular Therapeutics Incorporated, Opthea Limited, Eyepoint Pharmaceuticals Incorporated, Ocular Therapeutix Incorporated, OcuTerra Therapeutics Incorporated, Ocuphire Pharma Incorporated, Kubota Vision Incorporated, Amgen Incorporated, Coherus BioSciences Incorporated, Formycon AG, Alimera Sciences Incorporated, Neurotech Pharmaceuticals Incorporated, Alkeus Pharmaceuticals Incorporated, Aerie Pharmaceuticals Incorporated, Acucela Incorporated

Global Choroidal Neovascularization Market Trends and Insights

Major companies operating in the choroidal neovascularization market are focusing on developing innovative therapies, such as photodynamic therapy, to provide eye care professionals with precise, efficient treatment options that improve patient outcomes and treatment delivery. Photodynamic therapy (PDT) is a medical treatment that uses a photosensitizing agent activated by light to target and destroy abnormal or cancerous cells. For instance, in February 2023, Bausch & Lomb, a Canada-based healthcare company, and Modulight, a Finland-based biomedical company, announced the ML6710i photodynamic laser approved by the Food and Drug Administration, a US-based federal agency. This therapy is approved for the use with Bausch + Lomb’s VISUDYNE therapy, designed to treat choroidal neovascularization caused by age-related macular degeneration (AMD). This modern, mobile ophthalmic laser offers a targeted approach to treating abnormal blood vessels in the eye, helping to prevent further disease progression and preserve vision.

What Are Latest Mergers And Acquisitions In The Choroidal Neovascularization Market?

In March 2024, Sandoz Group AG, a Switzerland-based pharmaceutical company, acquired CIMERLI business from Coherus for $170 Million. With this acquisition, Sandoz Group AG aims to expand its portfolio in the ophthalmic sector by acquiring the CIMERLI business from Coherus, enhancing its ability to offer innovative treatments for retinal diseases, such as age-related macular degeneration (AMD). Coherus BioSciences is a US-based biopharmaceutical company that focuses on the research and development of diseases such as choroidal neovascularization.

Regional Outlook

North America was the largest region in the choroidal neovascularization market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Choroidal Neovascularization Market?

The choroidal neovascularization market consists of revenues earned by entities by providing services such as diagnostic services, therapeutic services, and follow-up and monitoring services. The market value includes the value of related goods sold by the service provider or included within the service offering. The choroidal neovascularization market also includes sales of injections, therapy agents, and surgical & laser devices. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Choroidal Neovascularization Market Report 2026?

The choroidal neovascularization market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the choroidal neovascularization industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.